EP Wealth Advisors LLC Purchases Shares of 15,401 TransMedics Group, Inc. $TMDX

Key Points

• EP Wealth Advisors acquired 15,401 TransMedics Group shares worth approximately $1.02 million in the second quarter. Institutional investors collectively own 99.67% of the company.
• Analyst sentiment is mixed: the stock has a consensus “Hold” rating and an average price target of $124.18, with some firms maintaining bullish views while others downgraded the shares.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings of $0.44 per share missed the $0.50 consensus forecast. The stock opened at $94.77, well below its 12-month high of $156.00.

EP Wealth Advisors LLC purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,401 shares of the company's stock, valued at approximately $1,023,000.

A number of other hedge funds have also modified their holdings of the business. Silvant Capital Management LLC acquired a new position in shares of TransMedics Group in the second quarter valued at approximately $26,000. Harvest Fund Management Co. Ltd purchased a new position in shares of TransMedics Group in the 3rd quarter worth about $29,000. North Star Investment Management Corp. acquired a new position in TransMedics Group during the first quarter valued at approximately $30,000. Ascentis Independent Advisors acquired a new position in shares of TransMedics Group during the 1st quarter valued at $30,000. Finally, Allworth Financial LP lifted its stake in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company's stock worth $30,000 after purchasing an additional 113 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares of the company's stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on TMDX shares. TD Cowen reaffirmed a "buy" rating and issued a $120.00 price objective on shares of TransMedics Group in a research report on Wednesday, July 1st. Zacks Research lowered shares of TransMedics Group from a "hold" rating to a "strong sell" rating in a report on Monday, July 6th. Weiss Ratings cut shares of TransMedics Group from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, July 28th. Piper Sandler reaffirmed an "overweight" rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Finally, Oppenheimer cut TransMedics Group from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, TransMedics Group has a consensus rating of "Hold" and an average target price of $124.18.

TransMedics Group Stock Performance

TMDX stock opened at $94.77 on Monday. The firm has a market cap of $3.28 billion, a P/E ratio of 24.36 and a beta of 1.90. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The stock's 50 day simple moving average is $77.49 and its 200 day simple moving average is $95.05. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. During the same period last year, the firm posted $0.92 earnings per share. The company's quarterly revenue was up 20.7% on a year-over-year basis. As a group, equities research analysts predict that TransMedics Group, Inc. will post 1.47 EPS for the current year.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source